Search
Thursday 1 October 2015
  • :
  • :
Latest Update

Current Trade News Analysis on: ARMOUR Residential REIT, (NYSE:ARR), Zillow Group, Class A (NASDAQ:ZG), TrovaGene (NASDAQ:TROV), Intercontinental Exchange (NYSE:ICE)

During Tuesday’s Current trade, Shares of ARMOUR Residential REIT, Inc. (NYSE:ARR), lost -0.84% to $20.12.

RMOUR Residential REIT, Inc. (NYSE: ARR, ARR PrA and ARR PrB) (“ARMOUR” or the “Company”) recently declared the October 2015 predictable cash dividend rate for the Company’s Common Stock.

October 2015 Common Stock Dividend Information

Month Dividend Holder of Record Date Payment Date

October 2015 $0.33 October 15, 2015 October 27, 2015

ARMOUR Residential REIT, Inc. invests in and manages a portfolio of residential mortgage backed securities in the United States. The company is managed by ARMOUR Capital Administration LP.

Shares of Zillow Group, Inc.- Class A (NASDAQ:ZG), inclined 0.43% to $28.35, during its current trading session.

More than a quarter of homes across the country lost value over the past year, despite the ongoing housing market recovery, according to the Zillow® August Real Estate Market Report. Some markets have already surpassed home values reached at the height of the housing bubble, while other markets are struggling to leave the recession behind.

Nationally, homes appreciated 3.3 percent from a year ago, rising to a Zillow Home Value Index of $180,800. The national growth rate has leveled off over the past five months, suggesting the housing recovery is ending and the market is returning to normal. However, 27.9 percent of homes lost value over the past year. Before the housing market crashed, an average of 21.2 percent of homes were losing value. In December 2008, 81.6 percent of homes lost value, the highest amount during the recession.

Markets on the East Coast and in the Midwest had the highest share of homes that lost value. A staggering 48.1 percent of homes in Baltimore reduced in value over the past year. Philadelphia (43.4 percent) and Washington, DC (41.2 percent) also had large shares of homes losing value.

Zillow Group, Inc. operates real estate and home-related information marketplaces on mobile and the Web in the United States. It offers a portfolio of brands and products to assist people find vital information about homes, and connect with local professionals. The company product portfolio comprises Zillow, a real estate and rental marketplace dedicated to consumers with data, inspiration, and knowledge around the place they call home, and connecting them with the local professionals who can assist; and Trulia, a home shopping marketplace, focused on giving home buyers, sellers, and renters the information they need to make better decisions about where to live.

TrovaGene Inc (NASDAQ:TROV), during its Tuesday’s current trading session gained 1.89% to $5.38.

Trovagene, Inc. (TROV), a developer of cell-free molecular diagnostics, declared that clinical data featuring its urine-based HPV HR Test were presented at the 30th International Human Papillomavirus Conference in Lisbon, Portugal. Adriana Lorenzi, a research fellow at the Institute of Education and Research and Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII Foundation, Barretos, Brazil, presented the results recently in Oral Session: PS36 Public Health. The presentation is entitled High-Risk HPV Detection in Urine Samples from a Brazilian Referral Population.

In the trial, urine samples collected from women preceding to treatment of cervical pre-cancer lesions (referral population) were tested with Trovagene’s HPV HR Test, and results were contrast to Roche’s cobas® HPV Test results from cervical samples. The trial results were comprising with formerly stated Predictors 4 data, which demonstrated that sensitivity with Trovagene’s HPV HR Test for the detection of CIN2+ and CIN3+ were comparable to other established cervical screening tests. In the Brazilian cohort, 271 cases of CIN2+ and 202 cases of CIN3+ disease were tested.

Trovagene, Inc., (TROV) a developer of cell-free molecular diagnostics, declared recently the establishment of Trovagene Research Institute (TRI), a European partner focused on expanding the capabilities and adoption of the Company’s Precision Cancer Monitoring℠ (PCM) platform. Alberto Bardelli, Ph.D., an internationally recognized leader in cell-free DNA cancer research, will be the Scientific Chair of TRI. Dr. Bardelli, presently associated with the Department of Oncology, Torino Medical School and the Candiolo Cancer Institute in Italy, was among the first to identify mutations in the kinase genes associated with colorectal cancer and other malignancies while at Johns Hopkins University. He has authored or co-authored over 140 published papers, counting his team’s most recent widely acclaimed publication in Nature Medicine1, entitled Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Trovagene, Inc., (TROV) a developer of cell-free molecular diagnostics, declared recently the establishment of Trovagene Research Institute (TRI), a European partner focused on expanding the capabilities and adoption of the Company’s Precision Cancer Monitoring℠ (PCM) platform. Alberto Bardelli, Ph.D., an internationally recognized leader in cell-free DNA cancer research, will be the Scientific Chair of TRI. Dr. Bardelli, presently associated with the Department of Oncology, Torino Medical School and the Candiolo Cancer Institute in Italy, was among the first to identify mutations in the kinase genes associated with colorectal cancer and other malignancies while at Johns Hopkins University. He has authored or co-authored over 140 published papers, counting his team’s most recent widely acclaimed publication in Nature Medicine1, entitled Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines

Finally, Intercontinental Exchange Inc (NYSE:ICE), decreased -0.05%, to $227.86.

Intercontinental Exchange (ICE), the leading global network of exchanges and clearing houses, declared that ICE Futures U.S. will launch a World Cotton contract on November 2, 2015. The World Cotton contract will price delivery of multiple origins and allow delivery in multiple locations around the world. The new contract will trade alongside ICE’s benchmark Cotton No. 2® contract.

Intercontinental Exchange, Inc. operates a network of regulated exchanges and clearing houses for financial and commodity markets in the United States, the United Kingdom, Continental Europe, Israel, Canada, and Singapore.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.




Leave a Reply

Your email address will not be published. Required fields are marked *